DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection

European Journal of Immunology

Volumn 37, Issue 2, 2007, Pages 376-384

  Brulet, Jean Marc ^a   Maudoux, Frédéric ^a   Thomas, Séverine ^a   Thielemans, Kris ^b   Burny, Arsène ^a   Leo, Oberdan ^a   Bex, Françoise ^a   Hallez, Sophie ^a,c  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c NONE   (Belgium)

Author keywords

Antigen presentation; CD4+ cells; Cytotoxic T lymphocytes; Human papillomavirus; Vaccination

Indexed keywords

DNA VACCINE; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN E7; B LYMPHOCYTE ANTIGEN; CANCER VACCINE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PAPILLOMA VIRUS VACCINE; UBIQUITIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG TREATMENT FAILURE; ENDOSOME; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SPACE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; ANIMAL; CONFOCAL MICROSCOPY; FEMALE; FLOW CYTOMETRY; GENE VECTOR; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INVARIANT CHAIN; METABOLISM; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; ENDOSOMES; FEMALE; FLOW CYTOMETRY; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICROSCOPY, CONFOCAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PLASMIDS; RECOMBINANT FUSION PROTEINS; TRANSFECTION; UBIQUITIN; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA;

EID: 33947728349     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200636233     Document Type: Article

References (33)

1. zur Hausen, H. H., Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2002. 2: 342-350.
2. Bosch, F. X., Munoz, N. and de Sanjose, S., Human papillomavirus and other risk factors for cervical cancer. Biomed. Pharmacother. 1997 51: 268-275.
3. Frazer, I. H., Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 2004. 4: 46-54.
4. Schlecht, N. F., Platt, R. W., Duarte-Franco, E., Costa, M. C., Sobrinho, J. P., Prado, J. C., Ferenczy, A. et al., Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 2003. 95: 1336-1343.
5. Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T. et al., Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A Randomized, controlled trial. Obstet. Gynecol. Surv. 2005. 60: 303-305.
6. Munger, K., Scheffner, M., Huilbregtse, J. M. and Howley, P. M., Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv. 1992. 12: 197-217.
7. Boyer, S. N., Wazer, D. E. and Band, V., E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996. 56: 4620-4624.
8. Mantovani, F. and Banks, L., The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001. 20: 7874-7887
9. Feltkamp, M. C., Smits, H. L., Vierboom, M. P., Minnaar, R. P., de Jongh, B. M., Drijfhout, J. W., ter Schegget, J. et al., Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 1993. 23: 2242-2249.
10. Hsu, K. F., Hung, C. F., Cheng, W. F., He, L., Slater, L. A., Ling, M. and Wu, T. C., Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther. 2001. 8: 376-383.
11. Cheng, W. F., Hung, C. H., Chai, C. Y., Hsu, K. F., He, L., Ling, M. and Wu, T. C., Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J. Virol. 2001. 75: 2368-2376.
12. Wang, T. L., Ling, M., Shih, I. M., Pham, T., Pai, S. I., Lu, Z., Kurman, R. J. et al., Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther. 2000. 7: 726-733.
13. Cohen, A. D., Boyer, J. D. and Weiner, D. B., Modulating the immune response to genetic immunization. FASEB J. 1998. 12: 1611-1626.
14. Kowalczyk, D. W. and Ertl, H. C., Immune responses to DNA vaccines. Cell Mol. Life Sci. 1999. 55: 751-770.
15. Tuting, T., Storkus, W. J. and Falo, I. D. J., DNA immunization targeting the skin: Molecular control of adaptive immunity. J. Invest. Dermatol. 1998. 111: 183-188.
16. Rodriguez, F., Zhang, J. and Whitton, J. L., DNA immunization: Ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 1997. 71: 8497-8503.
17. Reinstein, E., Scheffner, M., Oren, M., Ciechanover, A. and Schwartz, A., Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: Targeting via ubiquitination of the N-terminal residue. Oncogene 2000. 19: 5944-5950.
18. Lin, K. Y., Guarnieri, F. G., Staveley-O'Carroll, K. F., Levitsky, H. I., August, J. T., Pardoll, D. M. and Wu, T. C., Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996. 56: 21-26.
19. Ji, H., Wang, T. L., Chen, C. H., Pai, S. L, Hung, C. F., Lin, K. Y., Kurman, R. J. et al., Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum. Gene Ther. 1999. 10: 2727-2740.
20. Watkins, C., Hopkins, J. and Harkiss, G., Reporter gene expression in dendritic cells after gene gun administration of plasmid DNA. Vaccine 2005. 23: 4247-4256.
21. Zwaveling, S., Ferreira Mota, S. C., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H. and Melief, C. J., Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 2002. 169: 350-358.
22. Ben Saadon, R., Fajerman, I., Ziv, T., Hellman, U., Schwartz, A. L. and Ciechanover, A., The tumor suppressor protein p16(INK4a) and the human papillomavirus oncoprotein-58 E7 are naturally occurring lysine-less proteins that are degraded by the ubiquitin system. Direct evidence for ubiquitination at the N-terminal residue. J. Biol. Chem. 2004. 279: 41414-41421.
23. Santin, A. D., Hermonat, P. L., Ravaggi, A., Chiriva-Internati, M., Zhan, D., Pecorelli, S., Parham, G. P. and Cannon, M. J., Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16-and 18-positive cervical cancer. J. Virol. 1999. 73: 5402-5410.
24. Muderspach, L., Wilczynski, S., Roman, L., Bade, L., Felix, J., Small, L. A., Kast, W. M. et al., A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 2000. 6: 3406-3416.
25. Kadish, A. S., Timmins, P., Wang, Y., Ho, G. Y., Burk, R. D., Ketz, J., He, W., Romney, S. L. et al., Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol. Biomarkers Prev. 2002. 11: 483-488.
26. Hopfl, R., Heim, K., Christensen, N., Zumbach, K., Wieland, U., Volgger, B., Widschwendter, A. et al., Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 2000. 356: 1985-1986.
27. Sarkar, A. K., Tortolero-Luna, G., Follen, M. and Sastry, K. J., Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. Gynecol. Oncol. 2005. 99: S251-S261.
28. Visser, J., van Baarle, D., Hoogeboom, B. N., Reesink, N., Klip, H., Schuuring, E., Nijhuis, E. et al., Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia. Int. J. Cancer 2006. 118: 2529-2537.
29. Hallez, S., Detremmerie, O., Giannouli, C., Thielemans, K., Gajewski, T. F., Burny, A. and Leo, O., Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int. J. Cancer 1999. 81: 428-437.
30. De Marco, F., Hallez, S., Brulet, J. M., Gesche, F., Marzano, P., Flamini, S., Marcante, M. L. and Venuti, A., DNA vaccines against HPV-16 E7-expressing tumour cells. Anticancer Res. 2003. 23: 1449-1454.
31. Giannouli, C., Brulet, J. M., Gesche, F., Rappaport, J., Burny, A., Leo, O. and Hallez, S., Fusion of a tumour-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer. Anticancer Res. 2003. 23: 3523-3531.
32. Desaintes, C., Hallez, S., Van Alphen, P. and Burny, A., Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type 16. J. Virol. 1992. 66: 325-333.
33. Pajak, B., De Smedt, T., Moulin, V., De Trez, C., Maldonado-Lopez, R., Vansanten, G., Briend, E. et al., Immunohistowax processing, a new fixation and embedding method for light microscopy, which preserves antigen immunoreactivity and morphological structures: Visualisation of dendritic cells in peripheral organs. J. Clin. Pathol. 2000. 53: 518-524.